-
1.发明授权Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy 有权用于确定受试者是否将受益于共受体抑制剂治疗的组合物和方法公开(公告)号：US09581595B2
公开(公告)日：2017-02-28
申请号：US12527863
申请日：2008-02-26
IPC分类号： G01N33/00 , G01N33/569
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/56988 , G01N2333/16 , G01N2333/162 , G01N2800/52
摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
摘要翻译： 本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。 在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性 艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。
-
2.发明申请Methods and Compositions for Determining Anti-HIV Drug Susceptibility and Replication Capacity of HIV 审中-公开确定艾滋病毒抗艾滋病毒药物敏感性和复制能力的方法和组成公开(公告)号：US20090215028A1
公开(公告)日：2009-08-27
申请号：US11884668
申请日：2006-02-16
CPC分类号： C12N15/86 , C12N2740/16043 , G01N33/5008
摘要： This invention relates, in part, to methods and compositions for determining the susceptibility of an HIV to an anti-HIV drug or the replication capacity of an HIV. In certain embodiments, the methods comprise culturing a host cell in the presence of the anti-HIV drug, measuring the activity of the indicator gene in the host cell; and comparing the activity of the indicator gene as measured with a reference activity of the indicator gene. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the anti-HIV drug, thereby determining the susceptibility of the HIV to the anti-HIV drug. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity indicates the replication capacity of the HFV, thereby determining the replication capacity of the HIV. In certain embodiments, the host cell comprises a patient-derived segment and an indicator gene. In certain embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase or RNAse H.
摘要翻译： 本发明部分涉及用于确定HIV与抗HIV药物的易感性或HIV复制能力的方法和组合物。 在某些实施方案中，所述方法包括在抗HIV药物存在下培养宿主细胞，测量宿主细胞中指示基因的活性; 并将指示基因的活性与指示基因的参考活性进行比较。 在某些实施方案中，指示基因相对于参考活性的测量活性之间的差异与HIV对抗HIV药物的易感性相关，从而确定HIV对抗HIV药物的易感性。 在某些实施方案中，指示基因相对于参考活性的测量活性之间的差异表明HFV的复制能力，从而确定HIV的复制能力。 在某些实施方案中，宿主细胞包含患者来源的区段和指示基因。 在某些实施方案中，患者来源的区段包含编码整合酶或RNA酶H的核酸序列。
-
3.发明授权Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs 有权确定HIV-1与抗HIV药物易感性变化的方法和组合物公开(公告)号：US08071284B2
公开(公告)日：2011-12-06
申请号：US11916632
申请日：2006-06-06
申请人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
发明人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703 , C12Q2600/156
摘要： This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.
摘要翻译： 本发明部分地涉及用于确定人类免疫缺陷病毒（“HIV”）对非核苷逆转录酶抑制剂（“NNRTI”）依法韦仑（“EFV”），奈韦拉平（“NVP”）的改变的易感性的方法和组合物， ）和地拉呋啶（“DLV”），核苷逆转录酶抑制剂AZT和整合酶链转移抑制剂二酮酸1，二酮酸2和L-870,810，通过检测编码基因中的突变或突变的组合的存在 与抗HIV药物易感性改变相关的HIV逆转录酶。
-
4.发明申请Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs 有权确定HIV-1与抗HIV药物易感性变化的方法和组合物公开(公告)号：US20090136915A1
公开(公告)日：2009-05-28
申请号：US11916632
申请日：2006-06-06
申请人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
发明人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703 , C12Q2600/156
摘要： This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.
摘要翻译： 本发明部分地涉及用于确定人类免疫缺陷病毒（“HIV”）对非核苷逆转录酶抑制剂（“NNRTI”）依法韦仑（“EFV”），奈韦拉平（“NVP”）的改变的易感性的方法和组合物， ）和地拉呋啶（“DLV”），核苷逆转录酶抑制剂AZT和整合酶链转移抑制剂二酮酸1，二酮酸2和L-870,810，通过检测编码基因中的突变或突变的组合的存在 与抗HIV药物易感性改变相关的HIV逆转录酶。
-
5.发明授权Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs 有权确定HIV-1与抗HIV药物易感性变化的方法和组合物公开(公告)号：US08637252B2
公开(公告)日：2014-01-28
申请号：US13296370
申请日：2011-11-15
申请人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
发明人： Soumi Gupta , Signe Fransen , Ellen Paxinos , Neil T. Parkin
CPC分类号： C12Q1/703 , C12Q2600/156
摘要： This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.
摘要翻译： 本发明部分地涉及用于确定人类免疫缺陷病毒（“HIV”）对非核苷逆转录酶抑制剂（“NNRTI”）依法韦仑（“EFV”），奈韦拉平（“NVP”）的改变的易感性的方法和组合物， ）和地拉呋啶（“DLV”），核苷逆转录酶抑制剂AZT和整合酶链转移抑制剂二酮酸1，二酮酸2和L-870,810，通过检测编码基因中的突变或突变的组合的存在 与抗HIV药物易感性改变相关的HIV逆转录酶。
-
-
-
-
搜索结果
5 条记录 (耗时 0.029 秒)
